Ingrid A. Mayer

32.4k citations

210 papers · 12.0k indexed · 5 hit papers · h-index 46

Impact in

Cancer Research top 0.2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology

Papers in

Oncology 150
- HER2/EGFR in Cancer Research 75
- Cancer Treatment and Pharmacology 58
Cancer Research 57
- Breast Cancer Treatment Studies 41
- Cancer Genomics and Diagnostics 19

Co-authors: Carlos L. Arteaga Melinda E. Sanders Justin M. Balko Luca Gianni Giampaolo Bianchini Vandana G. Abramson Hope S. Rugo Dejan Juric
Journals: Journal of Clinical Oncology (61 papers)Cancer Research (30 papers)Clinical Cancer Research (12 papers)Annals of Oncology (12 papers)Breast Cancer Research and Treatment (7 papers)
Partner nations: United States Spain Germany

In The Last Decade

Ingrid A. Mayer

203 papers receiving 11.8k citations

Hit Papers

5 papers align trajectories log scale

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 2020 · 371 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 Annals of Oncology
2019 New England Journal of Medicine
2019 New England Journal of Medicine
2016 Nature Reviews Clinical Oncology
2015 Annual Review of Medicine

Peers

Countries citing papers authored by Ingrid A. Mayer

Since Specialization

Citations

This map shows the geographic impact of Ingrid A. Mayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingrid A. Mayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingrid A. Mayer more than expected).

Fields of papers citing papers by Ingrid A. Mayer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingrid A. Mayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingrid A. Mayer. The network helps show where Ingrid A. Mayer may publish in the future.

Co-authors

The 25 scholars most cited alongside Ingrid A. Mayer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ingrid A. Mayer Line = papers co-authored together Ingrid A. Mayer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	354TiP A phase III randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2– early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1) Annals of Oncology ·Erika Hamilton, Sibylle Loibl, Naoki Niikura, Priya Rastogi, Kamal S. Saini, Ioanna Gioni, Teresa Klinowska, Ingrid A. Mayer, Melissa K. Stuart, Emilia Syta, Andrew Walding, Thomas Bachelot	2023	3
2	Use of focused computerized cognitive training (Neuroflex) to improve symptoms in women with persistent chemotherapy-related cognitive impairment Digital Health ·Jennifer N. Vega, Paul Newhouse, Alexander C. Conley, Sarah M. Szymkowicz, Xuewen Gong, Sarah Côté, Ingrid A. Mayer, Warren D. Taylor, Sarah Shizuko Morimoto	2023	3
3	Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer Cancer Research Communications ·Margaret L. Axelrod, Yu Wang, Yaomin Xu, Xiaopeng Sun, Cosmin A. Bejan, Paula I. González-Ericsson, Sara Nunnery, Riley E. Bergman, Joshua Donaldson, Ángel Guerrero‐Zotano, Chiara Massa, Barbara Seliger, Melinda E. Sanders, Ingrid A. Mayer, Justin M. Balko	2022	5
4	Racial/Ethnic Disparities in All-Cause Mortality among Patients Diagnosed with Triple-Negative Breast Cancer Cancer Research ·Fei Wang, Wei Zheng, Christina E. Bailey, Ingrid A. Mayer, Jennifer A. Pietenpol, Xiao‐Ou Shu	2020	19
5	Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy Breast Cancer Research and Treatment ·Carly Bess Scalise, Caroline A. Nebhan, Jinming Yang, Lauren S. Starnes, Chi Yan, Anna E. Vilgelm, Sheau‐Chiann Chen, Gregory D. Ayers, Vandana G. Abramson, Ingrid A. Mayer, Ann Richmond	2020	6
6	Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer Clinical Cancer Research ·Fei Wang, Sonya Reid, Wei Zheng, Tuya Pal, Ingrid M. Meszoely, Ingrid A. Mayer, Christina E. Bailey, Ben Ho Park, Xiao‐Ou Shu	2019	12
7	Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer New England Journal of Medicine ·Fabrice André, Eva Ciruelos, Gábor Rubovszky, Mario Campone, Sibylle Loibl, Hope S. Rugo, Hiroji Iwata, Pierfranco Conté, Ingrid A. Mayer, Bella Kaufman, Toshinari Yamashita, Yen‐Shen Lu, Kenichi Inoue, Masato Takahashi, Zsuzsanna Pápai, Anne-Sophie Longin, David Mills, Celine Wilke, Samit Hirawat, Dejan Juric Hit paper breakdown →	2019	1565
8	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer npj Breast Cancer ·Mellissa J. Nixon, Luigi Formisano, Ingrid A. Mayer, Mónica V. Estrada, Paula I. González-Ericsson, Steven J. Isakoff, Andres Forero‐Torres, Helen Won, Melinda E. Sanders, David B. Solit, Michael F. Berger, Lewis C. Cantley, Eric P. Winer, Carlos L. Arteaga, Justin M. Balko	2019	28
9	Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial Journal of Clinical Oncology ·Aditya Bardia, Marina Parton, Sherko Kümmel, Laura García‐Estévez, Chiun‐Sheng Huang, Javier Cortés, Manuel Ruíz‐Borrego, Melinda L. Telli, Paloma Martín-Martorell, Rafael López‐López, J. Thaddeus Beck, Roohi Ismail‐Khan, Shin‐Cheh Chen, Sara A. Hurvitz, Ingrid A. Mayer, D. Carreon, Scott B. Cameron, Serena G. Liao, José Baselga, Sung‐Bae Kim	2018	55
10	PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K α Inhibitors Clinical Cancer Research ·Sarah Croessmann, Jonathan H. Sheehan, Kyung‐min Lee, Gregory Sliwoski, Jie He, Rebecca J. Nagy, David R. Riddle, Ingrid A. Mayer, Justin M. Balko, Richard B. Lanman, Vincent A. Miller, Lewis C. Cantley, Jens Meiler, Carlos L. Arteaga	2017	27
11	PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses Clinical Cancer Research ·Jiqing Sai, Philip Owens, Sergey V. Novitskiy, Oriana E. Hawkins, Anna E. Vilgelm, Jinming Yang, Tammy Sobolik, Nicole Lavender, Andrew C. Johnson, Colt M. McClain, Gregory D. Ayers, Mark C. Kelley, Melinda E. Sanders, Ingrid A. Mayer, Harold L. Moses, Mark Boothby, Ann Richmond	2016	89
12	ecancermedicalscience ecancermedicalscience ·Carrie G. Lenneman, Wissam Abdallah, Holly Smith, Vandana G. Abramson, Ingrid A. Mayer, Cheri Silverstein, Cheri Silverstein, Julie Means‐Powell, Sachin Y. Paranjape, Daniel J. Lenihan, Douglas B. Sawyer, Satish R. Raj	2016	13
13	Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer Cancer Research ·Neil E. Bhola, Valerie M. Jansen, Sangeeta Bafna, Jennifer M. Giltnane, Justin M. Balko, Mónica V. Estrada, Ingrid M. Meszoely, Ingrid A. Mayer, Vandana G. Abramson, Fei Ye, Melinda E. Sanders, Teresa C. Dugger, Eliezer M. Van Allen, Carlos L. Arteaga	2014	50
14	New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity Clinical Cancer Research ·Ingrid A. Mayer, Vandana G. Abramson, Brian D. Lehmann, Jennifer A. Pietenpol	2014	229
15	Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer Clinical Cancer Research ·Ke‐Da Yu, Rui Zhu, Ming Zhan, Angel Rodriguez, Wei Yang, Stephen Wong, Andreas Makris, Brian D. Lehmann, Xi Chen, Ingrid A. Mayer, Jennifer A. Pietenpol, Zhi‐Ming Shao, W. Fraser Symmans, Jenny C. Chang	2013	127
16	Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006 Journal of Clinical Oncology ·Mothaffar F. Rimawi, Ingrid A. Mayer, Andres Forero, Rita Nanda, Matthew P. Goetz, Angel Rodriguez, Anne C. Pavlick, Tao Wang, Susan G. Hilsenbeck, Carolina Gutiérrez, Rachel Schiff, C. Kent Osborne, Jenny C. Chang	2013	187
17	Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report Medical Oncology ·Wade T. Iams, Kathyrn Eby Beckermann, Anne T. Neff, Ingrid A. Mayer, Vandana G. Abramson	2013	15
18	A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer Physics in Medicine and Biology ·Xia Li, E. Brian Welch, Lori R. Arlinghaus, A. Bapsi Chakravarthy, Lei Xu, Jaime Farley, Mary E. Loveless, Ingrid A. Mayer, Mark C. Kelley, Ingrid M. Meszoely, Julie A. Means‐Powell, Vandana G. Abramson, Ana M. Grau, John C. Gore, Thomas E. Yankeelov	2011	54
19	Motion correction in diffusion‐weighted MRI of the breast at 3T Journal of Magnetic Resonance Imaging ·Lori R. Arlinghaus, E. Brian Welch, A. Bapsi Chakravarthy, Lei Xu, Jaime Farley, Vandana G. Abramson, Ana M. Grau, Mark C. Kelley, Ingrid A. Mayer, Julie A. Means‐Powell, Ingrid M. Meszoely, John C. Gore, Thomas E. Yankeelov	2011	26
20	Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation Clinical Cancer Research ·Joshua A. Bauer, A. Bapsi Chakravarthy, Jennifer M. Rosenbluth, Deming Mi, Erin H. Seeley, Nara De Matos Granja-Ingram, Maria G. Olivares, Mark C. Kelley, Ingrid A. Mayer, Ingrid M. Meszoely, Julie A. Means‐Powell, Kimberly N. Johnson, C. Jillian Tsai, Gregory D. Ayers, Melinda E. Sanders, Robert J. Schneider, Silvia C. Formenti, Richard M. Caprioli, Jennifer A. Pietenpol	2010	142

About Ingrid A. Mayer

Ingrid A. Mayer is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 210 papers that have together received 12.0k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (85 papers), HER2/EGFR in Cancer Research (75 papers), Cancer Treatment and Pharmacology (58 papers), Breast Cancer Treatment Studies (41 papers), PI3K/AKT/mTOR signaling in cancer (40 papers), Cancer Genomics and Diagnostics (19 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Estrogen and related hormone effects (15 papers). The work is most often cited by research in Cancer Research (3.4k citations), Oncology (6.0k citations), Pulmonary and Respiratory Medicine (3.3k citations), Genetics (941 citations) and Radiology, Nuclear Medicine and Imaging (1.8k citations). Ingrid A. Mayer has collaborated with scholars based in United States, Spain and Germany. Frequent co-authors include Carlos L. Arteaga, Melinda E. Sanders, Justin M. Balko, Luca Gianni, Giampaolo Bianchini, Vandana G. Abramson, Hope S. Rugo, Dejan Juric, Paula R. Pohlmann and Ray Mernaugh. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, Annals of Oncology and Breast Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact